Pharmaceuticals, Biotechnology and Life Sciences
Closing conditions waived – Amended & Restated Partnership Agreement is now closed Acerus-Aytu jointly led commercial effort behind NATESTO® in…
Closing conditions waived – Amended & Restated Partnership Agreement is now closed Acerus-Aytu jointly led commercial effort behind NATESTO® in…
– Companies to Initiate Phase 3 Trial to Support Global Registrations – BOTHELL, Wash. & TOKYO–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN)…
– Companies to Initiate Phase 3 Trial to Support Global Registrations – BOTHELL, Wash. & TOKYO–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN)…
– Trial rapidly enrolled in 8 months – Trial size expanded to accommodate 24 more patients than planned SAN FRANCISCO–(BUSINESS…
– Trial rapidly enrolled in 8 months – Trial size expanded to accommodate 24 more patients than planned SAN FRANCISCO–(BUSINESS…
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, and Pierre Fabre have agreed to extend the terms of…
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, and Pierre Fabre have agreed to extend the terms of…
DAEJEON, South Korea–(BUSINESS WIRE)–#ALTB4—Alteogen Inc. (KOSDAQ:196170) announced today that it has entered into a non-exclusive global license agreement with a…
DAEJEON, South Korea–(BUSINESS WIRE)–#ALTB4—Alteogen Inc. (KOSDAQ:196170) announced today that it has entered into a non-exclusive global license agreement with a…